首页|达格列净联合利拉鲁肽治疗2型糖尿病的效果及其作用机制

达格列净联合利拉鲁肽治疗2型糖尿病的效果及其作用机制

扫码查看
目的 探讨达格列净联合利拉鲁肽治疗 2 型糖尿病的效果及其作用机制.方法 选取 2019 年5月至2022年5月收治的130例2型糖尿病患者为研究对象,以随机数字表法将其分为对照组和观察组,各 65例.对照组采用利拉鲁肽治疗,观察组采用达格列净联合利拉鲁肽治疗.比较两组的治疗效果.结果 治疗后,观察组的平均血糖(MBG)、血糖水平标准差(SDBG)、餐后血糖波动幅度(PPGE)低于对照组(P<0.05).治疗后,观察组的胰岛素抵抗指数(HOMA-IR)低于对照组,胰岛β细胞功能指数(HOMA-β)高于对照组(P<0.05).治疗后,观察组的肿瘤坏死因子-α(TNF-α)、纤溶酶原激活剂抑制物-1(PAI-1)、胱抑素C(CysC)水平低于对照组(P<0.05).治疗后,观察组的Nesfatin-1、热休克蛋白60(HSP60)水平低于对照组(P<0.05).结论 达格列净联合利拉鲁肽有利于降低2型糖尿病患者的血糖波动、胰岛素抵抗,下调TNF-α、PAI-1、CysC、Nesfatin-1、HSP60水平,值得推广.
Effect and mechanism of dagliquin combined with liraglutide in the treatment of type 2 diabetes mellitus
Objective To investigate the effect and mechanism of dagliquin combined with liraglutide in the treatment of type 2 diabetes mellitus.Methods A total of 130 patients with type 2 diabetes admitted from May 2019 to May 2022 were selected as the research objects and divided into control group and observation group by random number table method,with 65 cases in each group.The control group was treated with liraglutide,and the observation group was treated with dagliquin combined with liraglutide.The therapeutic effects of the two groups were compared.Results After treatment,the mean blood glucose(MBG),standard deviation of blood glucose(SDBG)and postprandial glucose excursions(PPGE)in the observation group were lower than those in the control group(P<0.05).After treatment,the homeostasis model assessment-insulin resistance index(HOMA-IR)in the observation group was lower than that in the control group,and the homeostasis model assessment-β(HOMA-β)was higher than that in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),plasminogen activator inhibitor-1(PAI-1)and cystatin C(CysC)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of Nesfatin-1 and heat shock protein 60(HSP60)in the observation group were lower than those in the control group(P<0.05).Conclusion Dagliquin combined with liraglutide is beneficial to reduce blood glucose fluctuation and insulin resistance in patients with type 2 diabetes mellitus,and down-regulate the levels of TNF-α,PAI-1,CysC,Nesfatin-1 and HSP60,which is worthy of promotion.

dagliquinliraglutidetype 2 diabetes mellitusdynamic blood glucoseinsulin resistance

魏素滨、倪娜、雷烨、赵云汉

展开 >

长武县人民医院,陕西 咸阳,713600

汉中市勉县医院,陕西 汉中,723000

陕西中医药大学第二附属医院,陕西 咸阳,712000

新疆医科大学,新疆 乌鲁木齐,830011

展开 >

达格列净 利拉鲁肽 2型糖尿病 动态血糖 胰岛素抵抗

陕西中医药大学第二附属医院学科创新团队项目(2020)

2020XKTD-C01

2024

临床医学研究与实践

临床医学研究与实践

ISSN:
年,卷(期):2024.9(10)
  • 15